
|Videos|August 6, 2014
Strategies for Overcoming <em>KRAS</em> Mutations in Lung Cancer
Author(s)David Gandara, MD
David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcoming KRAS mutations in lung cancer.
Advertisement
Clinical Pearls
David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcomingKRASmutations in lung cancer. Gandara presented on this topic at the
- KRASmutations tend to predict less response to chemotherapy or TKIs.
- It has been extremely difficult to develop drugs that directly inhibit KRAS.
- MEK inhibitors in combination with chemotherapy have shown downstream activity.
- SWOG 1408 will test this hypothesis with a MEK inhibitor (trametinib) in combination with chemotherapy (docetaxel) or an AKT inhibitor (GSK795).
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 TROPION-Lung17 Trial Initiates TROP2-Directed Therapy in NSCLC
2
FDA Receives BLA for Ivonescimab in EGFR+ NSCLC
3
FDA Grants Orphan Drug Designation for Gotistobart in Squamous NSCLC
4
For a Second Time, FDA Denies Approval of Tab-Cel in EBV+ PTLD
5
















































